Moleculin Biotech announced the positive discussion in and outcome of its End of Phase 1B/2 meeting with the U.S. FDA supporting the advancement of Annamycin in combination with Cytarabine to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy. This Phase 3 “MIRACLE” trial will be a global trial, including sites in the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech files to sell common stock, warrants, no amount given
- Moleculin Biotech Advances AML Treatment After FDA Meeting
- Moleculin Biotech completes End of Phase 2 meeting with FDA for Annamycin
- Moleculin Biotech Announces Promising Annamycin Trial Results
- Moleculin Biotech reports data from Phase 1B/2 (MB-106) clinical trial
Questions or Comments about the article? Write to editor@tipranks.com